Role of continuous glucose monitoring device on diabetes patient

Efficacy of continuous glucose monitoring for glycaemic control over standard treatment and monitoring in individuals with uncontrolled type 2 diabetes in Khordha district: A randomized control trial. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/062647

Enrollment

Registered

2024-02-14

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Continuous Glucose Monitoring (CGM): In the intervention arm, Individuals will be provided with a continuous glucose monitoring (CGM) device for 14 days. The sensor, worn under the skin

Eligibility

Inclusion criteria

Inclusion criteria: Individuals with type 2 diabetes on 3 or more oral antidiabetic agents with or without insulin HbA1C more than 7%.

Exclusion criteria

Exclusion criteria: Individuals with type 1 diabetes Gestational diabetes mellitus Individuals with diabetic complications (acute or chronic) Individuals with a history of bleeding disorder Individuals with a recent history of steroid use

Design outcomes

Primary

Measure	Time frame
attainment of glycemic control (HbA1c less than 7) Mean reduction in HbA1c level Timepoint: 3months 6months	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactNibash K

AIIMS Bhubaneswar

cmfm_priyamadhaba@aiimsbhubaneswar.edu.in9910830997

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026